Affiliation
Breast Cancer Family History Clinic, Nightingale Center, Withington Hospital, South Manchester University Hospital Trust, Manchester, UK. andrew.maurice@smuht.nwest.nhs.ukIssue Date
2006
Metadata
Show full item recordAbstract
The impact of chemoprevention trials can be hampered by poor participant compliance with the study medication. We used medication monitoring systems and pill count data to try to establish factors that may predict compliance with the International Breast Intervention Study (IBIS) and whether the participants went on to complete or benefit the trial. Women who took their trial medication in a regular pattern rather than randomly were more likely to be of benefit to the study (p = 0.003). For those women who failed to complete the study, compliance was shown to gradually reduce at each follow-up appointment. The taking of additional prescribed medication and not smoking were important factors in predicting completion (p = 0.04 and p = 0.047, respectively) and benefit (p = 0.037 and p = 0.031, respectively) to the study. Taking these factors into account when advising women at the start of a chemoprevention trial may be helpful in improving compliance.Citation
Predicting compliance in a breast cancer prevention trial., 12 (5):446-50 Breast JJournal
The Breast JournalDOI
10.1111/j.1075-122X.2006.00295.xPubMed ID
16958964Type
ArticleLanguage
enISSN
1075-122Xae974a485f413a2113503eed53cd6c53
10.1111/j.1075-122X.2006.00295.x
Scopus Count
Collections
Related articles
- Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
- Authors: Loehberg CR, Jud SM, Haeberle L, Heusinger K, Dilbat G, Hein A, Rauh C, Dall P, Rix N, Heinrich S, Buchholz S, Lex B, Reichler B, Adamietz B, Schulz-Wendtland R, Beckmann MW, Fasching PA
- Issue date: 2010 May
- How to decrease the non-compliance in a clinical trial.
- Authors: Baratelli GM, Allio W, Lanzani A, Valsecchi P, Rotmensz N
- Issue date: 2002 Feb
- Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.
- Authors: Taylor R, Taguchi K
- Issue date: 2005 May-Jun
- Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer.
- Authors: Yeomans Kinney A, Vernon SW, Shui W, Weber DV, Schell M, Vogel VG
- Issue date: 1998 Jul
- Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
- Authors: Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE
- Issue date: 2008 Apr 20